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TO AUTOLOGOUS DENDRITIC/MYELOMA FUSION VACCINE DEVELOPED
FOR THE TREATMENT OF MULTIPLE MYELOMA
Rosenblatt, J.1, Glotzbecker, B.1, Mills, H.1, Keefe, W.1, Wellenstein, K.1,
Vasir, B.2, Wu, Z.2, Zarwan, C.1, Schickler, M.3, Rotem-Yehudar, R.3,
Kufe, D.2, Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston,
MA; 2Dana-Farber Cancer Institute, Boston, MA; 3CureTech, Ltd.,
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We have developed a cancer vaccine in which autologous mye-
loma cells are fused with dendritic cells (DCs) resulting in the pre-
sentation of tumor antigens in the context of DC mediated
costimulation. In animal models, vaccination with fusion cells re-
sults in eradication of established tumor, and in clinical trials,
both immunologic and clinical responses have been observed.
However, response to vaccination may be muted by inhibitory sig-
nals such as the PD1/PDL1 pathway which blunt activated T cell
responses. In this study, we evaluated expression of PD1 on T cells
derived from patients with multiple myeloma (MM), and PDL1
expression on primary myeloma cells and DC/MM fusions. We
evaluated the effect of PD-1 blockade on T cell response to
DC/MM fusion cell vaccination in vitro. Tumor cells were ob-
tained from bone marrow aspirates of MM patients. Nonadherent
peripheral blood mononuclear cells (PBMCs) obtained from pa-
tients with MM and normal volunteers were cultured in RPMI
supplemented with 10U/ml IL-2, and expression of PD-1 on
CD4 +T cells was assessed by flow cytometry. DCs were gener-
ated from adherent PBMCs cultured with rhIL-4, GM-CSF and
TNFa and fused with MM cells by coculture in 50% solution of
PEG. T cells were stimulated by DC/MM fusions in the presence
or absence of PD-1 blockade. We demonstrate that PD-1 expres-
sion is markedly upregulated on T cells in patients with advanced
MM. As compared to a control population in which mean levels of
PD-1 expression was 6% (n5 7), mean expression in patients with
MM was 20% (n5 9). Mean expression of PDL-1 was 66% on pa-
tient derived MM cells (n5 3) and. 90% on DC/MM fusions
(n5 2), which potentially provides an inhibitory signal dampening
fusion mediated immunologic response. We examined the effect of
PD-1 blockade on T cell response to DC/MM fusions ex vivo. En-
hanced fusion mediated stimulation of T cells was noted in the
presence of anti-PD-1, resulting in a greater than 5 fold increase
in T cell proliferation. Interferon gamma secretion by CD4 +T
cells in response to stimulation by DC/MM fusions increased
from 4% to 11% in the presence of PD1 blockade, while IL-10
secretion decreased from 6.5% to 3.5%. In summary, we demon-
strate that PD-1 expression is increased in T cells of MM patients,
and PD-1 blockade enhances activated T cell responses following
stimulation with a DC/MM fusion vaccine. A clinical trial in which
MM patients are treated with DC/MM fusions in conjunction with
anti-PD1 is planned.213
CYTOKINE LEVELS IN PATIENTS WITH PLASMA CELL DISORDERS (PCD)
UNDERGOING PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT)
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Background:We reported increased rates of engraftment syndrome
(ES) and associated morbidity in POEMS patients undergoing
PBSCT. The condition is successfully treated with early institution
of corticosteroids. We postulated that the high rates of ES in these
patients relates to their pre-existing aberrant cytokine milieu.
Methods:To test this hypothesis, we prospectively collected plasma
samples from patients undergoing PBSCT on day -2, 1, 4, 7, 10, 17
and 20. Charts were abstracted independent of knowledge of cyto-
kine information. Cytokine levels were run using BioSource Multi-
plex Bead Immunoassays Platform (Human cytokine 30-PLEX)–
30 different human cytokines, chemokines and growth factors. ES
was defined according to published criteria by Maiolino et al.
(BMT 2003) allowing for more liberal time relative to neutrophil en-
graftment.Results: A total of 18 patients were sampled: 9 POEMS, 4 multiple
myeloma (MM), and 5 amyloidosis (AL). Baseline characteristics are
summarized in Table 1. POEMS patients had higher median pre-
transplant levels of IL-4 (14.9 v 2.9 pg/mL p50.03), IL-10 (14.3 v
10.7 pg/mL, p5 0.004), EGF (31.7 v 0.0 pg/mL, p5 0.001), and
IFN-a (39.4 v 0.0 pg/mL, p5 0.01) than the patients with the other
PCDs. IP-10 was lower in POEMS patients (21.7 vs 43.1 pg/mL
p5 0.02). Day -2 plasma VEGF level was not significantly higher
in POEMS patients presumably since 67% of them received chemo-
therapy prior to PBSCT. Five patients developed ES – 2 POEMS, 2
AL and 1 MM – at a median of 10 days (range 8-13). Lower levels of
IL-1Ra and IL-15 post-transplant were associated with increased
risk of ES, p\0.05. Delayed engraftment of neutrophils correlated
with higher levels of IL-13 and EGF pre- and post-transplant.
Conclusion: These data are provocative in that they demonstrate
that prior to transplantation, the cytokine milieu differs between
POEMS patients and those with other PCDs, that EGF and IL-13
may predict for delayed engraftment, and that lower levels of IL-
1Ra and IL-15 may be associated with increased risk of ES. Larger
numbers of patients will be required to validate our findings.
Patient Characteristics
POEMS non-POEMS
(n5 9) (n5 9)% %Age in years, median (range) 52 (35-68) 62 (50-70)
Gender, M 44 89
Caucasian race 67 89
KPS, median (range) 70 (50-80) 90 (70-100)
Polyneuropathy 100 0
Organomegaly 78 11
Endocrinopathy 100 11
Skin Involvement 78 0
Extravascular fluid overload 100 44
Sclerotic bone lesions 67 0
Castleman’s dz 56 0
Splenomegaly 56 0
Papilledema 22 0
Prior treatments, median (range) 2 (1-4) 1 (0-7)
Chemo prior to transplant 67 78
Conditioning, Mel 200 67 78
Mobilization, G alone 89 67
CD34 infused, (x106/kg), median
(range)
3.88 (2.9-14.6) 4.93 (3.45-7.49)Engraftment syndrome 22 33
Engraftment*, days, median (range)
ANC. 500/uL 15 (13-19) 13 (12-15)
Platelets. 20/uL 11 (0-20) 13 (11-20)
Platelets. 50/uL 14 (12-27) 15 (12-25)*two non-POEMS patients died prior to platelet engraftment214
A NOVEL HAPLO-IDENTICAL ADOPTIVE CTL THERAPY AS TREATMENT
FOR EBV-ASSOCIATED LYMPHOMA AFTER STEM CELL TRANSPLANTA-
TION
Uhlin, M.1, Okas, M.1, Gertow, J.1, Uzunel, M.1, Brismar, T.2,
Mattsson, J.1 1Karolinska University Hospital Huddinge, Stockholm,
Sweden; 2Karolinska University Hospital Huddinge, Stockholm, Sweden
Epstein-Barr virus (EBV) related malignancies such as post-trans-
plant lymphoproliferative disease (PTLD) are severe complications
after allogeneic stem cell transplantation (SCT) and solid organ
transplantation. In immune suppressed transplant recipients the ac-
tivity of EBV-specific CTLs are often decreased or absent which
leads to an increased risk of developing PTLD. If primary treatment
modalities of PTLD fail, the most efficient way of treating the ma-
lignancy is adopting EBV-specific CTLs from the donor or, more
recently, third-party donors. This is however both time-consuming
and expensive and often it is too late to administer cells to the patient.
